With the announcement that Google has completely reorganized its entire business under a new parent company called Alphabet, there are still many questions floating around about what products belong with what companies now.
Thanks to Google’s SEC filing, we’ve got some answers on that front.
I missed out scooping the Google Glass skydiving unveil at Google I/O 2012 because I didn’t believe my source. He knew about the entire thing, but it was too unbelievable for me to post. I’m posting this late word from my source because I think there is a small chance that Google announces it tomorrow (by posting late, it hopefully won’t go mainstream and I don’t look like an idiot when it doesn’t happen).
According to the source, Google has some biomedical superstars working in its X Lab on some cutting-edge micro bots that can detect things like certain kinds of cancer. These bots are small enough (the size of blood cells) to fit through human capillaries, yet they can detect diseases in the blood and can trigger an RFID reader, which in turn talks to a watch – perhaps a device running Android Wear. I was told this technology is at least 2 years from being a real product (and likely more when you consider FDA and public outcry). This isn’t the first time we’ve heard of nanobots circulating human bloodstreams, with scientists working on the idea as far back as 2009.
The bots would circulate in your blood stream, and when they went through your wrist (under your watch), the watch would be capable of reading the status (cancer/no cancer etc.).
Similar technology is already well documented and in recent years has become closer to something Google could actually use in a product. Ray Kurzweil, futurist and director of engineering at Google, described his vision for nanobots that could enter our blood stream in a piece he penned for The Guardian back in 2007:
Expand
Expanding
Close
